Compare Fubotv Inc (FUBO) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Fubotv Inc trades at $8.22 (market cap $894.32M), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Fubotv Inc and Maravai LifeSciences Holdings Inc. Class A Common Stock are close in size by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Fubotv Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| FUBO | MRVI | |
|---|---|---|
Market Cap | $894.32M | $972.90M |
Volume | 1,279,134 | 4,325,710 |
Sector | Media | Health |
52-Week High | $48.96 | $9.00 |
52-Week Low | $8.09 | $2.83 |
Typical Hold Time | 35 Days | 0 Days |
Enterprise Value | $1.07B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO stock trades at $8.19, down 6.29% today, reflecting a bearish technical signal. Revenue grew to $1.62 billion in 2024, with net losses narrowing to -$172.25 million, indicating improving profitability trends. The company recently expanded sports streaming partnerships, including a multi-year NHL deal announced September 28, 2026, to enhance content offerings.
The outlook is mixed; deep undervaluation metrics like P/S of 0.16 and analyst consensus price target of $63.38 suggest significant upside, but persistent cash burn and competitive pressures in streaming pose risks. Investor sentiment hinges on execution of Disney-backed turnaround plans targeting $300 million EBITDA by FY28.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
